Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study DOI Open Access
Anita Gąsiorowska, Marek Romanowski, Ewa Walecka‐Kapica

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 6 - 6

Published: Dec. 24, 2024

Objective: Biotics are increasingly being used in the treatment of irritable bowel syndrome (IBS). This study aimed to assess efficacy and safety a mixture microencapsulated sodium butyrate, probiotics (Lactocaseibacillus rhamnosus DSM 26357, Lactobacillus acidophilus 32418, Bifidobacterium longum 32946, bifidum 32403, lactis 32269), short-chain fructooligosaccharides (scFOSs) IBS patients. Methods: was randomized, double-blind, placebo-controlled trial involving 120 adult participants with IBS. The primary outcome 12-week intervention improvement symptoms quality life (QOL), assessed use IBS-Adequate Relief (IBS-AR), IBS-Global Improvement Scale (IBS-GIS), IBS-Symptom Severity Score (IBS-SSS), IBS-QOL. Secondary outcomes were number type stools (assessed via Bristol Stool Form scale), patient-recorded symptoms, anthropometric parameters, levels selected inflammatory cytokines. Results: As early as at 4 weeks, there higher percentage patients biotic group reporting adequate relief (based on IBS-AR) than placebo (64.7% vs. 42.0%, respectively, p = 0.023). At 12 fewer reported ‘worsening symptoms’ IBS-GIS) (5.9% 16.0% 0.015). There no significant differences between groups IBS-QOL or IBS-SSS any secondary measures except ‘urgency defecate’ (p 0.015) week 12, which significantly lower group. safe well tolerated. Conclusions: A consisting probiotics, small amounts scFOSs is effective improving gastrointestinal

Language: Английский

Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial DOI Open Access

Nozomi Matsuura,

Masaya Kanayama,

Yuta Watanabe

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(19), P. 3333 - 3333

Published: Oct. 1, 2024

Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects prebiotics/probiotics can vary depending on IBS subtypes. The purpose this study was investigate personalized prebiotic probiotic supplements based intestinal microbiota subtypes in patients. Methods: Patients with diarrhea-type (IBS-D), constipation-type (IBS-C), mixed-type (IBS-M) were enrolled (n = 40 per group; total: n 120). Personalized determined according microbiota. patients received for 4 weeks. primary outcome change IBS-severity scoring system from baseline week 4. Results:The significantly decreased all (−38.0 [95% confidence interval (CI): −53.6, −22.4]; p < 0.001), IBS-D (−44.5 CI: −70.6, −18.5]; 0.004) IBS-C (−51.2 −79.4, −22.9]; 0.002), but not those IBS-M (−20.0 −48.0, 8.1]; 0.47). In study, no serious adverse events observed that had a causal relationship intervention. Conclusions: conclusion, selected individual subtype may alleviate severity symptoms, particularly IBS-D.

Language: Английский

Citations

4
The role of colonic microbiota amino acid metabolism in gut health regulation DOI Creative Commons
Youli Chen, Jing‐Yuan Fang

Cell Insight, Journal Year: 2025, Volume and Issue: unknown, P. 100227 - 100227

Published: Jan. 1, 2025

The human gut microbiota plays a critical role in maintaining host homeostasis through metabolic activities. Among these, amino acid (AA) metabolism by the large intestine is highly heterogeneous and relevant to health. Despite increasing interest, microbial AA remains relatively unexplored. This review highlights recent advances colonic metabolism, including auxotrophies, synthesis, dissimilatory metabolites, their implications health, focusing on major gastrointestinal diseases colorectal cancer, inflammatory bowel disease, irritable syndrome.

Language: Английский

Citations

0
Abordagens terapêuticas na síndrome do intestino irritável, comparação da eficácia e impacto na qualidade de vida das terapias farmacológicas, biológicas e dietéticas no manejo dos sintomas DOI Creative Commons

Victoria Figueiredo Lemos,

Alberto David Bekerman,

Ana Amaral

et al.

Contribuciones a las Ciencias Sociales, Journal Year: 2025, Volume and Issue: 18(1), P. e14698 - e14698

Published: Jan. 17, 2025

Introdução: A Síndrome do Intestino Irritável (SII) é uma condição gastrointestinal crônica que afeta principalmente mulheres entre 15 e 60 anos, caracterizando-se por desconforto abdominal alterações intestinais. fisiopatologia envolve fatores como hipersensibilidade visceral disbiose intestinal, tornando o tratamento complexo requerendo abordagens personalizadas. Objetivo: Avaliar as terapêuticas para manejo da SII, comparando a eficácia impacto das terapias farmacológicas, biológicas dietéticas na qualidade de vida dos pacientes. Metodologia: Revisão integrativa com buscas nas bases PubMed SciELO, selecionando analisando estudos originais sobre limitações intervenções discutidas. Resultados: rifaximina foi eficaz sintomas dor urgência fecal, mas resultados inconsistentes. linaclotida mostrou boa abdominal, lubiprostona constipação. Terapias hipnoterapia apresentaram resposta positiva (40,8%). Probióticos transplante microbiota fecal (TMF) também mostraram benefícios. Discussão: teve variáveis, enquanto eficaz, apesar efeitos adversos. dieta Low-FODMAP bons resultados, dificuldades adesão. Psicoterapia antidepressivos se úteis. falta padronização longo prazo destacam necessidade mais pesquisas. Conclusão: linaclotida, óleo hortelã-pimenta são eficazes, adesão adversos representam desafios. combinação psicoterapêuticas promissora, novas pesquisas biomarcadores necessários otimizar tratamento.

Citations

0
Resolution of long-term severe irritable bowel syndrome following fecal microbiota transplantation: A case report and microbiota analysis DOI Creative Commons

Elena Montenegro-Borbolla,

Jeanine Wakim El‐Khoury, Claire Bertelli

et al.

Gut Microbes Reports, Journal Year: 2025, Volume and Issue: 2(1)

Published: April 20, 2025

Language: Английский

Citations

0
(Poly)phenol-gut microbiota interactions and their impact on human health DOI
Xiaohe Liu, Amnah A. Alharbi, Rachel Gibson

et al.

Current Opinion in Clinical Nutrition & Metabolic Care, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

Purpose of review (Poly)phenols are bioactive compounds in plant-based foods with well documented health benefits. Their metabolism dependent on gut microbiota composition, diversity, and function, which modulate their bioavailability physiological effects. This examines recent insights into (poly)phenol-gut interactions, emphasizing relevance mediating benefits mechanisms action. Recent findings studies have identified a high interindividual variability (poly)phenol metabolism, explored microbial-derived metabolites potential benefits, revealed bidirectional influences between (poly)phenols composition. Advances analytical techniques large-scale refined our understanding these but inconsistencies remain linking specific microbial signatures to outcomes. Summary Standardized methodologies long-term needed clarify the impact (poly)phenol-derived human health. Future research should focus personalized targeted nutrition approaches optimize

Language: Английский

Citations

0
Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024 DOI Creative Commons
J.M. Remes-Troche, Enrique Coss‐Adame, Max J. Schmulson

et al.

Revista de Gastroenterología de México (English Edition), Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

The aim of this position statement is to provide health professionals with an updated and evidence-based guideline for the pharmacologic management irritable bowel syndrome (IBS) in Mexico. A literature review was conducted that included relevant guidelines studies, up date its publication. mechanism action, specific indications IBS, safety profile, availability each therapeutic class were evaluated. recommendations developed by 14 experts, considering clinical reality IBS patients Specific issued class. Antispasmodics (alone or combined) are used as first-line therapy pain management, whereas antidiarrheals, such loperamide, reducing diarrhea diarrhea-predominant (IBS-D) laxatives constipation constipation-predominant (IBS-C). 5-HT4 agonists (prucalopride mosapride) recommended IBS-C 5-HT3 antagonists (ondansetron) IBS-D. Linaclotide only secretagogue available Mexico IBS-C. Rifaximin-alpha stands out efficacy a subgroup IBS-D mixed IBS. Probiotics conditionally adjuvant due heterogeneous evidence. Neuromodulators (tricyclic antidepressants, selective serotonin reuptake inhibitors, etc.) second-line treatment management. Mesalazine can be IBS-D, but corresponding evidence weak. Overall, these solid framework personalizing treatment, based on characteristics Mexican patient

Language: Английский

Citations

0
Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease DOI Creative Commons
Jianchun Duan, Qinmei Li, Yan Cheng

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(12)

Published: Dec. 1, 2024

Abstract Increasing evidences indicate that the gut microbiota is involved in development and therapy of gastrointestinal hepatic disease. Imbalance occurs early stages diseases, maintaining balance provides a new strategy for treatment diseases. It has been reported Parabacteroides distasonis associated with multiple As next‐generation probiotics, several studies have demonstrated its positive regulation on disease, including inflammatory bowel colorectal cancer, fibrosis, fatty liver. The function P. metabolites mainly affect host immune system, intestinal barrier function, metabolic networks. Manipulation natural components lead to protective effect enterohepatic In this review, pathways regulated by are summarized illustrate active their impact metabolism, role action mechanism disease discussed. More importantly, can be used manipulate as strategies, challenges perspectives clinical applications

Language: Английский

Citations

3
Impact of Microbiota on Irritable Bowel Syndrome Pathogenesis and Management: A Narrative Review DOI Creative Commons

Mhd Bashir Almonajjed,

Mahdi Wardeh,

Abdallah Atlagh

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(1), P. 109 - 109

Published: Jan. 13, 2025

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder, affecting 3–5% of the global population and significantly impacting patients’ quality life healthcare resources. Alongside physical symptoms such as abdominal pain altered habits, many individuals experience psychological comorbidities, including anxiety depression. Recent research has highlighted critical role gut microbiota in IBS, with dysbiosis, characterized by an imbalance microbial diversity, frequently observed patients. The gut–brain axis, bidirectional communication network between central nervous system, plays development IBS symptoms. Although interventions probiotics, prebiotics, synbiotics, fecal transplantation (FMT) have demonstrated potential modulating alleviating symptoms, their efficacy remains area ongoing investigation. This review examines interactions microbiota, immune brain, emphasizing need for personalized therapeutic strategies. Future should aim to identify reliable microbiota-based biomarkers refine microbiome-targeted therapies enhance patient outcomes.

Language: Английский

Citations

0
Post-infectious irritable bowel syndrome: Focus on serotonin metabolism disturbances and gut microbiota modulation DOI
О. В. Гаус,

Aliza Fedorenko,

А. Н. Судакова

et al.

Medical alphabet, Journal Year: 2025, Volume and Issue: 34, P. 36 - 41

Published: Jan. 24, 2025

Post-infectious irritable bowel syndrome (PI–IBS) is the first phenotype of disease described in literature and most studied to date. The prevalence PI–IBS population continues grow steadily especially post-COVID-19 pandemic period. Taking into account accumulated scientific clinical data dysfunction functional axis «microbiota-gut-brain» associated with formation visceral hypersensitivity intestinal motor disorders due abnormal serotonin metabolism, increased permeability low-grade inflammation considered as a key pathogenetic factor underlying development persistence symptoms. This review article analyzes summarizes information on mechanisms changes neurohumoral regulation, well qualitative quantitative composition microbiota. In addition, possibility using probiotic therapy complex patients are presented.

Language: Английский

Citations

0
Tratamiento farmacológico del síndrome de intestino irritable en México. Posicionamiento de la Asociación Mexicana de Gastroenterología 2024 DOI Creative Commons
J.M. Remes-Troche, Enrique Coss‐Adame, Max J. Schmulson

et al.

Revista de Gastroenterología de México, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Citations

0